Table 1 Demographic and clinical characteristics of the study population.

From: Association evidence of CCTTT repeat polymorphism in the iNOS promoter and the risk of atrial fibrillation in Taiwanese

 

Controls (n = 240)

AF patients (n = 200)

P

Age, years

55.7 ± 7.6

56.9 ± 8.4

0.14

Gender (M/F)

172/68

145/55

0.85

BMI, kg/m2

25.3 ± 3.2

25.5 ± 4.5

0.68

Hypertension, n (%)

126 (52.5)

119 (59.5)

0.14

Diabetes mellitus, n (%)

17 (7.1)

21 (10.5)

0.20

Smoking, n (%)

62 (25.8)

45 (22.6)

0.43

Hypercholesterolemia, n (%)

25 (10.4)

21 (10.5)

0.98

CAD, n (%)

5 (2.1)

10 (5.0)

0.09

paroxysmal/persistent, n (%)

—

109/91 (54.5/45.5)

 

LA dimension > 40 mm, n (%)

—

86 (43.0)

 

ARB, n (%)

65 (27.1)

83 (41.5)

<0.001

ACE inhibitor, n (%)

15 (6.2)

11 (5.5)

0.74

β-blocker, n (%)

56 (23.3)

88 (44.0)

<0.001

Calcium antagonist, n (%)

71 (29.6)

79 (39.5)

0.03

Diuretic, n (%)

11 (4.6)

32 (16.0)

<0.001

Digoxin, n (%)

0 (0.0)

34 (17.0)

<0.001

Statin, n (%)

41 (17.1)

59 (29.5)

0.002

Aspirin, n (%)

17 (7.1)

85 (42.5)

<0.001

Oral anticoagulant, n (%)

0 (0.0)

38 (19.0)

<0.001

Systemic embolization, n (%)

0 (0.0)

9 (4.5)

0.001

  1. ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; BMI = body mass index; CAD = coronary artery disease; LA = left atrium.
Back to article page